PZRX - PhaseRx, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2806
0.0000 (0.0000%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2806
Open0.3000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2750 - 0.3400
52 Week Range0.2228 - 1.9500
Volume1,045,258
Avg. Volume1,670,847
Market Cap3.28M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1870
Earnings DateMar 26, 2018 - Mar 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • The Wall Street Journal19 days ago

    [$$] Roivant Sciences to Buy PhaseRx

    Swiss health-care company Roivant Sciences GmbH is the successful bidder in the auction for Seattle-based PhaseRx, which filed for chapter 11 bankruptcy in December less than two years after going public ...

  • The Wall Street Journal2 months ago

    [$$] Firm Retention Summary: PhaseRx Inc.

    This is a summary of a request from PhaseRx Inc. to hire Polsinelli PC as counsel, filed Dec. 14 with the U.S. Bankruptcy Court in Wilmington, Del.

  • PR Newswire2 months ago

    PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

    SEATTLE, Dec. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced it received a decision from the Nasdaq Hearings Panel (the "Panel") granting PhaseRx's request for continued listing on The Nasdaq Capital Market until January 31, 2018. On or before January 31, 2018, Company shall inform the Panel that the Section 363 sale is complete, at which time the shares will be delisted from the Nasdaq Stock Market. Should events occur that call into question the ability of the Company to complete the sale through the bankruptcy process on a timeline consistent with its representations at the hearing, it should so inform the Panel immediately.

  • PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News
    SmarterAnalyst2 months ago

    PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News

    Monday turned out to be a nightmare for PhaseRx Inc (NASDAQ:PZRX) investors after the biopharmaceutical firm announced that it has filed for Chapter 11 bankruptcy protection. PhaseRx expects to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. Contemporaneous with the filing of the Chapter 11 petition, the company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • The Wall Street Journal2 months ago

    [$$] PhaseRx, a Developer of Liver Drugs, Files for Bankruptcy

    PhaseRx Inc., a developer of drugs to treat life-threatening liver diseases in children, has filed for chapter 11 bankruptcy, about a year after going public with the backing of several venture capital ...

  • PR Newswire2 months ago

    PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

    SEATTLE, Dec. 11, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. PhaseRx intends to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • SmarterAnalyst3 months ago

    PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union

    Shares of PhaseRx Inc (NASDAQ:PZRX) skyrocket over 70% today, after the drug maker announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the Orphan Medicinal Product Application for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD). To be eligible for orphan medicinal product designation, the Company had to establish medically plausible evidence that PRX-ASL will provide a significant benefit over existing approved therapies in the European Union for the treatment of ASLD.

  • PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
    PR Newswire3 months ago

    PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

    SEATTLE, Nov. 28, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), PhaseRx's second drug candidate to treat a urea cycle disorder.

  • PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire3 months ago

    PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE , Nov. 9, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?
    Simply Wall St.4 months ago

    Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?

    Investors are always looking for growth in small-cap stocks like PhaseRx Inc (NASDAQ:PZRX), with a market cap of USD $8.07M. However, an important fact which most ignore is: how financiallyRead More...

  • PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options
    PR Newswire4 months ago

    PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

    SEATTLE, Oct. 26, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced receipt of a delisting notice from Nasdaq, which informed the company that, absent an appeal, trading in PhaseRx's common stock will be suspended from Nasdaq at the opening of business on November 1, 2017. PhaseRx will appeal the decision to a Nasdaq Hearing Panel, which will stay the suspension of their securities, pending the panel's decision subsequent to the hearing. PhaseRx received notification from the Listing Qualifications Department of the Nasdaq Stock Market on August 22, 2017, indicating that the company no longer complied with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.

  • ACCESSWIRE4 months ago

    Featured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate Restructuring

    LONDON, UK / ACCESSWIRE / October 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for PhaseRx, Inc. (NASDAQ: PZRX ), following which we have published ...

  • PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives
    PR Newswire4 months ago

    PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

    SEATTLE, Oct. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its board of directors has made a determination to conduct a restructuring of operations to reduce short term operating costs and delay the development of its lead product candidate PRX-OTC. The company has not set a timetable for this process. No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic alternatives will result in a transaction, or the terms or timing of any potential transaction that may take place.

  • PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency
    PR Newswire5 months ago

    PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency

    SEATTLE, Sept. 20, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its second drug development candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA). ASLD is a rare liver disorder caused by an inherited single-gene deficiency that results in hyperammonemia (elevated ammonia in the blood), and can lead to irreversible neurological impairment, coma and death.

  • PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire6 months ago

    PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE , Aug. 10, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire9 months ago

    PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE, May 12, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting
    PR Newswire10 months ago

    PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting

    SEATTLE, May 3, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster ...

  • Accesswire10 months ago

    Today's Research Reports on Stocks to Watch: Cempra and PhaseRx

    NEW YORK, NY / ACCESSWIRE / May 1, 2017 / U.S. markets fell Friday after data showed the U.S. economy grew at a slower than expected pace in the first quarter. The Dow Jones Industrial Average fell 0.19 ...

  • PhaseRx to Present Data at the TIDES Conference
    PR Newswire10 months ago

    PhaseRx to Present Data at the TIDES Conference

    SEATTLE, April 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a ...

  • PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
    PR Newswire10 months ago

    PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

    SEATTLE, April 25, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-OTC for the treatment of ornithine transcarbamylase deficiency (OTCD). OTCD is a rare genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase, an essential urea cycle enzyme that facilitates the break down and removal of ammonia from the body.

  • PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
    PR Newswire11 months ago

    PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

    SEATTLE, March 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PR Newswirelast year

    PhaseRx to Present at Upcoming Investor Conferences

    SEATTLE , Feb. 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced ...